Quince Therapeutics, Inc. Quarterly Entity Common Stock, Shares Outstanding from Q2 2019 to Q3 2024

Taxonomy & unit
dei: shares
Description
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
Summary
Quince Therapeutics, Inc. quarterly Entity Common Stock, Shares Outstanding history and growth rate from Q2 2019 to Q3 2024.
  • Quince Therapeutics, Inc. Entity Common Stock, Shares Outstanding for the quarter ending November 5, 2024 was 44M shares, a 2.64% increase year-over-year.
Entity Common Stock, Shares Outstanding, Quarterly (shares)
Entity Common Stock, Shares Outstanding, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q3 2024 44M +1.13M +2.64% Nov 5, 2024 10-Q 2024-11-13
Q2 2024 43.3M +6.89M +18.9% Aug 6, 2024 10-Q 2024-08-13
Q1 2024 43.2M +6.94M +19.1% Mar 25, 2024 10-K 2024-04-01
Q3 2023 42.9M +6.74M +18.7% Nov 6, 2023 10-Q 2023-11-14
Q2 2023 36.4M +279K +0.77% Jul 28, 2023 10-Q 2023-08-03
Q1 2023 36.3M +6.13M +20.3% Mar 10, 2023 10-K 2023-03-15
Q3 2022 36.1M +6.25M +20.9% Nov 4, 2022 10-Q 2022-11-09
Q2 2022 36.1M +6.42M +21.6% Aug 3, 2022 10-Q 2022-08-09
Q1 2022 30.2M +562K +1.9% May 3, 2022 10-Q 2022-05-10
Q3 2021 29.9M +380K +1.29% Oct 25, 2021 10-Q 2021-10-29
Q2 2021 29.7M +198K +0.67% Aug 3, 2021 10-Q 2021-08-06
Q1 2021 29.6M +186K +0.63% May 3, 2021 10-Q 2021-05-06
Q3 2020 29.5M +2.65M +9.85% Nov 11, 2020 10-Q 2020-11-12
Q2 2020 29.5M +2.65M +9.86% Aug 12, 2020 10-Q 2020-08-14
Q1 2020 29.4M Mar 13, 2020 10-K 2020-03-16
Q3 2019 26.9M Nov 12, 2019 10-Q 2019-11-12
Q2 2019 26.8M Jun 12, 2019 10-Q 2019-06-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.